Skip to content
Ketek(telithromycin)
Ketek, Levviax (telithromycin) is a small molecule pharmaceutical. Telithromycin was first approved as Ketek on 2001-07-09. It is used to treat bacterial infections in the USA. It has been approved in Europe to treat bacterial pneumonia, chronic bronchitis, community-acquired infections, pharyngitis, and pneumonia amongst others.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Telithromycin
Tradename
Company
Number
Date
Products
KETEKSanofiN-021144 DISCN2004-04-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ketekNew Drug Application2012-05-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA15: Telithromycin
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitis bD019694EFO_0004197B18.1331022440
Hepatitis bD006509—24129
Chronic hepatitisD006521K73.9———3—3
Liver cirrhosisD008103EFO_0001422K74.0——21—3
Chronic renal insufficiencyD051436N18———1—1
ViremiaD014766B34.9———1—1
Pregnancy complicationsD011248———1—1
Liver neoplasmsD008113EFO_1001513C22.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis b virusD006515——1—12
HepatitisD006505HP_0012115K75.9——1——1
Virus diseasesD014777B34—11——1
Breast neoplasmsD001943EFO_0003869C50——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289—1——12
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20————11
Esophageal neoplasmsD004938C15————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTELITHROMYCIN
INNtelithromycin
Description
Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C
Identifiers
PDB—
CAS-ID191114-48-4
RxCUI274786
ChEMBL IDCHEMBL1136
ChEBI ID—
PubChem CID3002190
DrugBankDB00976
UNII IDKI8H7H19WL (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,455 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ketek
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,229 adverse events reported
View more details